AIM ImmunoTech Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AIM NYSE American 2830 aimimmuno.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AIM ImmunoTech Inc.

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer - Nov 10th, 2025 6:55 am
AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting - Nov 4th, 2025 7:05 am
AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue - Nov 3rd, 2025 6:55 am
Zacks.com featured highlights include The Honest Company, Dutch, AIM ImmunoTech, Masimo and Cognizant Technology Solutions - Oct 23rd, 2025 6:51 am
Bet On 5 Top-Ranked Stocks With Rising P/E - Oct 22nd, 2025 10:02 am
AIM ImmunoTech to Attend the 2025 Maxim Growth Summit - Oct 20th, 2025 7:15 am
All You Need to Know About AIM ImmunoTech (AIM) Rating Upgrade to Buy - Oct 10th, 2025 10:00 am
AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors - Sep 25th, 2025 6:45 am
AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth - Sep 22nd, 2025 7:00 am
Maxim Group Sees 133% Upside in AIM ImmunoTech Inc. (AIM) - Sep 21st, 2025 7:10 am
AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland - Sep 4th, 2025 9:00 am
Advance Information Marketing Berhad Full Year 2025 Earnings: RM0.018 loss per share (vs RM0.023 loss in FY 2024) - Sep 2nd, 2025 4:51 pm
AIM ImmunoTech Announces Release of the Next CEO Corner Segment - Aug 21st, 2025 7:00 am
JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025 - Aug 15th, 2025 8:00 am
AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Aug 15th, 2025 7:00 am
AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - Aug 14th, 2025 6:55 am
FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates - Aug 11th, 2025 4:55 pm
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) - Aug 6th, 2025 7:00 am
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval - Aug 4th, 2025 7:00 am
AIM ImmunoTech Announces Closing of $8.0 Million Public Offering - Jul 31st, 2025 7:00 am